{"id":116428,"date":"2026-06-26T20:36:06","date_gmt":"2026-06-26T15:36:06","guid":{"rendered":"https:\/\/dailyausaf.com\/en\/?p=116428"},"modified":"2026-06-26T20:36:06","modified_gmt":"2026-06-26T15:36:06","slug":"new-pill-can-cure-86-of-baldness","status":"publish","type":"post","link":"https:\/\/dailyausaf.com\/en\/health\/new-pill-can-cure-86-of-baldness\/","title":{"rendered":"New pill can cure 86% of baldness"},"content":{"rendered":"

An experimental oral treatment for male pattern baldness<\/a> has produced encouraging results in a late-stage clinical trial, with 86% of participants reporting improved hair coverage after six months.<\/p>\n

US biopharmaceutical company Veradermics developed the drug, known as VDPHL01, as an extended-release version of oral minoxidil.<\/p>\n

However, the treatment has not yet been approved by the US Food and Drug Administration. It remains under clinical development and is not commercially available.<\/p>\n

The trial involved 519 men.<\/h2>\n

The Phase 2\/3 trial enrolled 519 men with mild to moderate pattern hair loss, also known as androgenetic alopecia.<\/p>\n

Researchers randomly assigned participants to three main groups.<\/p>\n

One group received 8.5mg of VDPHL01 once daily. The other took the same dose twice daily. The remaining participants received a placebo.<\/p>\n

The study used a randomized, double-blind, placebo-controlled design. This meant that neither the participants nor the investigators knew who was receiving the active treatment during the trial.<\/p>\n

Up <\/span>To <\/span>86% <\/span>Reported <\/span>Better <\/span>Hair <\/span>Coverage<\/span><\/span><\/h2>\n
Other <\/span>subjects <\/span>who <\/span>tried <\/span>the <\/span>oral <\/span>treatment <\/span>measured <\/span>their <\/span>hair <\/span>improvement <\/span>using <\/span>the <\/span>Androgenetic <\/span>Alopecia <\/span>Impact <\/span>Rating <\/span>Scale. <\/span><\/span>Of <\/span>those <\/span>taking <\/span>the <\/span>one-daily <\/span>dose, <\/span>79.3% <\/span>reported <\/span>an <\/span>improvement <\/span>in <\/span>hair <\/span>coverage. <\/span><\/span>For <\/span>those <\/span>who <\/span>took <\/span>the <\/span>two-daily <\/span>dose <\/span>of <\/span>the <\/span>treatment, <\/span>86% <\/span>of <\/span>the <\/span>subjects <\/span>found <\/span>they <\/span>had <\/span>better <\/span>coverage. <\/span><\/span><\/div>\n
<\/div>\n
Of <\/span>the <\/span>subjects <\/span>who <\/span>took <\/span>the <\/span>placebo <\/span>treatment, <\/span>only <\/span>35.6% <\/span>saw <\/span>an <\/span>improvement. <\/span><\/span><\/div>\n

Disclaimer<\/span><\/span><\/h2>\n
The <\/span>study <\/span>does <\/span>not <\/span>state <\/span>that <\/span>the <\/span>treatment <\/span>caused <\/span>an <\/span>86% <\/span>increase <\/span>in <\/span>hair <\/span>coverage; <\/span>it <\/span>states <\/span>that <\/span>86% <\/span>of <\/span>the <\/span>test <\/span>subjects <\/span>had <\/span>a <\/span>better <\/span>outcome <\/span>with <\/span>the <\/span>twice-daily <\/span>treatment <\/span>regimen. <\/span><\/span><\/div>\n
<\/div>\n
A <\/span>subset <\/span>of <\/span>tests <\/span>used <\/span>“improvement” <\/span>or <\/span>“much <\/span>improved” <\/span>as <\/span>criteria, <\/span>and <\/span>48.4% <\/span>and <\/span>62.9% <\/span>of <\/span>the <\/span>once- <\/span>and <\/span>twice-daily <\/span>groups, <\/span>respectively, <\/span>met <\/span>that. <\/span><\/span><\/div>\n
<\/div>\n
Just <\/span>13.4% <\/span>of <\/span>those <\/span>in <\/span>the <\/span>placebo <\/span>group <\/span>met <\/span>those <\/span>criteria. <\/span><\/span>Independent <\/span>investigators <\/span>looked <\/span>at <\/span>participants <\/span>and <\/span>found <\/span>increased <\/span>hair <\/span>coverage <\/span>with <\/span>both <\/span>once <\/span>and <\/span>twice-daily <\/span>dosing, <\/span>at <\/span>72% <\/span>and <\/span>84.4% <\/span>in <\/span>respective <\/span>groups <\/span>after <\/span>six <\/span>months. <\/span><\/span><\/div>\n
<\/div>\n
An oral <\/span>drug <\/span>offers <\/span>extended-release <\/span>of <\/span>minoxidil. <\/span>Minoxidil <\/span>has <\/span>been <\/span>available <\/span>as a <\/span>high <\/span>blood <\/span>pressure <\/span>medication <\/span>and <\/span>then <\/span>as <\/span>a <\/span>hair <\/span>regrowth <\/span>drug <\/span>that <\/span>comes <\/span>in <\/span>topical <\/span>forms <\/span>for <\/span>male <\/span>pattern <\/span>hair <\/span>loss. <\/span><\/span><\/div>\n
<\/div>\n
The <\/span>medication <\/span>has <\/span>also <\/span>been <\/span>given <\/span>by <\/span>some <\/span>doctors <\/span>orally <\/span>in <\/span>a <\/span>low <\/span>dosage <\/span>format, <\/span>even <\/span>though <\/span>instant-release <\/span>versions <\/span>were <\/span>never <\/span>designed <\/span>for <\/span>hair <\/span>loss. <\/span><\/span>Instead <\/span>of <\/span>a <\/span>new <\/span>active <\/span>drug, <\/span>VDPHL01 <\/span>involves <\/span>a <\/span>special <\/span>extended-release <\/span>composition <\/span>of <\/span>minoxidil, <\/span>where <\/span>it’s <\/span>embedded <\/span>within <\/span>a <\/span>matrix of gel<\/span>. <\/span><\/span>This, <\/span>developers <\/span>hope, <\/span>will <\/span>release <\/span>the <\/span>drug <\/span>over <\/span>longer <\/span>time <\/span>periods. <\/span><\/span><\/div>\n
<\/div>\n
Current <\/span>once <\/span>or <\/span>twice <\/span>daily <\/span>oral <\/span>minoxidil <\/span>quickly <\/span>rises <\/span>to <\/span>maximum <\/span>blood <\/span>concentration <\/span>levels <\/span>and is then eliminated<\/span>\u00a0<\/span>by <\/span>the <\/span>body <\/span>in <\/span>several <\/span>hours.<\/span><\/span><\/div>\n
<\/div>\n
“Continuous-release <\/span>of <\/span>minoxidil, <\/span>we <\/span>believe, <\/span>could <\/span>increase <\/span>prolonged <\/span>stimulation <\/span>of <\/span>hair <\/span>follicles <\/span>and <\/span>allow <\/span>for <\/span>a <\/span>flatter <\/span>profile, <\/span>thereby <\/span>avoiding <\/span>the <\/span>plasma <\/span>peak <\/span>levels <\/span>seen <\/span>with <\/span>immediate-release <\/span>oral <\/span>minoxidil <\/span>that <\/span>are <\/span>associated <\/span>with <\/span>cardiovascular <\/span>side <\/span>effects,” <\/span>a <\/span>Veradermics <\/span>press <\/span>release <\/span>stated. <\/span><\/span>Of <\/span>course, <\/span>regulators <\/span>must <\/span>also <\/span>review <\/span>the <\/span>complete <\/span>results <\/span>to <\/span>determine <\/span>if <\/span>the <\/span>new <\/span>drug <\/span>should <\/span>be <\/span>approved.<\/span><\/span><\/div>\n","protected":false},"excerpt":{"rendered":"

An experimental oral treatment for male pattern baldness has produced encouraging results in a late-stage clinical trial, with 86% of participants reporting improved hair coverage after six months. US biopharmaceutical company Veradermics developed the drug, known as VDPHL01, as an extended-release version of oral minoxidil. However, the treatment has not yet been approved by the […]<\/p>\n","protected":false},"author":9,"featured_media":13315,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,9],"tags":[43341],"class_list":["post-116428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-latest-news","tag-baldness"],"_links":{"self":[{"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/posts\/116428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/comments?post=116428"}],"version-history":[{"count":1,"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/posts\/116428\/revisions"}],"predecessor-version":[{"id":116429,"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/posts\/116428\/revisions\/116429"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/media\/13315"}],"wp:attachment":[{"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/media?parent=116428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/categories?post=116428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailyausaf.com\/en\/wp-json\/wp\/v2\/tags?post=116428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}